Clinical differences between idiopathic and scleroderma-related pulmonary hypertension

Arthritis and Rheumatism

Volumn 54, Issue 9, 2006, Pages 3043-3050

  Fisher, Micah R ^a   Mathai, Stephen C ^b   Champion, Hunter C ^b   Girgis, Reda E ^b   Housten Harris, Traci ^b   Hummers, Laura ^b   Krishnan, Jerry A ^b   Wigley, Fredrick ^b   Hassoun, Paul M ^b,c  

^a EMORY UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PROSTANOID; SILDENAFIL; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; SCLERODERMA; SURVIVAL; SURVIVAL RATE;

ADULT; BODY MASS INDEX; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULMONARY ARTERY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, LIMITED; SURVIVAL ANALYSIS;

EID: 33749329543     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22069     Document Type: Article

References (35)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl):5-12S.
5. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91.
6. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-9.
7. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):35-62S.
8. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
9. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
10. Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32:998-1006.
11. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105-13.
12. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
13. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
14. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.
15. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
17. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
18. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562-76.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
21. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
22. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9.
23. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
24. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-6.
25. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003;9:311-7.
26. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005;16:13-8.
27. Louie EK, Lin SS, Reynertson SI, Brundage BH, Levitsky S, Rich S. Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction. Circulation 1995;92:819-24.
28. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006;47:500-6.
29. Liang HY, Cauduro SA, Pellikka PA, Bailey KR, Grossardt BR, Yang EH, et al. Comparison of usefulness of echocardiographic Doppler variables to left ventricular end-diastolic pressure in predicting future heart failure events. Am J Cardiol 2006;97:866-71.
30. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32.
31. Hinderliter AL, Willis PW, Long W, Clarke WR, Ralph D, Caldwell EJ, et al, for the PPH Study Group. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension: primary pulmonary hypertension. Am J Cardiol 1999;84:481-4.
32. Miller AJ, Pick R, Johnson PJ. The production of acute pericardial effusion: the effects of various degrees of interference with venous blood and lymph drainage from the heart muscle in the dog. Am J Cardiol 1971;28:463-6.
33. Mellins RB, Levine OR, Fishman AP. Effect of systemic and pulmonary venous hypertension on pleural and pericardial fluid accumulation. J Appl Physiol 1970;29:564-9.
34. Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998;37:1320-3.
35. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003;42:71-5.